TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce that it has received regulatory approval to begin its Phase I clinical trial program. Health Canada issued a No Objection Letter in response to Antibe’s Clinical Trial Application allowing the company to initiate its study entitled ‘A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.’ This approval represents a significant milestone on Antibe’s well-defined pathway for the development of ATB-346.
Help employers find you! Check out all the jobs and post your resume.
